Vera Therapeutics, Inc. $VERA Shares Sold by Platinum Investment Management Ltd.

Platinum Investment Management Ltd. lowered its position in shares of Vera Therapeutics, Inc. (NASDAQ:VERA) by 25.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 119,384 shares of the company’s stock after selling 40,367 shares during the quarter. Vera Therapeutics makes up about 1.4% of Platinum Investment Management Ltd.’s holdings, making the stock its 16th largest holding. Platinum Investment Management Ltd. owned 0.19% of Vera Therapeutics worth $6,046,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. GAMMA Investing LLC raised its holdings in shares of Vera Therapeutics by 50.5% during the fourth quarter. GAMMA Investing LLC now owns 703 shares of the company’s stock valued at $36,000 after acquiring an additional 236 shares during the last quarter. Los Angeles Capital Management LLC acquired a new position in shares of Vera Therapeutics during the fourth quarter valued at approximately $46,000. Quantbot Technologies LP acquired a new position in shares of Vera Therapeutics during the second quarter valued at approximately $51,000. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Vera Therapeutics by 25.9% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,106 shares of the company’s stock valued at $157,000 after purchasing an additional 639 shares during the last quarter. Finally, Tower Research Capital LLC TRC increased its holdings in shares of Vera Therapeutics by 192.9% in the second quarter. Tower Research Capital LLC TRC now owns 4,186 shares of the company’s stock valued at $99,000 after purchasing an additional 2,757 shares during the last quarter. Institutional investors and hedge funds own 99.21% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently commented on the company. Wolfe Research raised Vera Therapeutics from a “peer perform” rating to an “outperform” rating and set a $88.00 price target for the company in a report on Wednesday, March 11th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vera Therapeutics in a report on Monday, April 20th. TD Cowen reaffirmed a “buy” rating on shares of Vera Therapeutics in a report on Tuesday, June 2nd. William Blair reaffirmed an “outperform” rating on shares of Vera Therapeutics in a report on Tuesday, June 2nd. Finally, The Goldman Sachs Group reaffirmed a “buy” rating and issued a $90.00 price target on shares of Vera Therapeutics in a report on Tuesday, June 2nd. Ten equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Vera Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $78.00.

Insiders Place Their Bets

In related news, CEO Marshall Fordyce sold 22,951 shares of the stock in a transaction that occurred on Tuesday, April 14th. The stock was sold at an average price of $44.05, for a total value of $1,010,991.55. Following the completion of the transaction, the chief executive officer directly owned 235,244 shares in the company, valued at approximately $10,362,498.20. This represents a 8.89% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 15.90% of the company’s stock.

Vera Therapeutics Price Performance

NASDAQ:VERA opened at $34.26 on Friday. Vera Therapeutics, Inc. has a one year low of $19.07 and a one year high of $56.05. The company has a debt-to-equity ratio of 0.15, a quick ratio of 13.64 and a current ratio of 13.64. The stock has a market cap of $2.46 billion, a PE ratio of -6.18 and a beta of 0.93. The stock has a 50 day moving average price of $37.02 and a 200 day moving average price of $41.38.

Vera Therapeutics (NASDAQ:VERA) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($1.69) EPS for the quarter, missing the consensus estimate of ($1.33) by ($0.36). During the same quarter in the previous year, the business earned ($0.81) earnings per share. Equities research analysts expect that Vera Therapeutics, Inc. will post -6.23 EPS for the current fiscal year.

Vera Therapeutics Profile

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.